 BOCA RATON, Fla., Aug. 18, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. AzurRx or the Company NASDAQ: AZRX, a company specializing in the development of targeted, non-systemic therapies for gastrointestinal GI diseases, today announced positive topline results from its Phase 2 Combination Trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy PERT, for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis CF. 